GSK3B and cancer: Consistently, we previously demonstrated that copper chelation therapy inhibited GSK3B phosphorylation and in turn induced downregulation of PD-L1 and increased anti-cancer immune response (Rouaen et al. 2022; Voli et al. 2020).